Investment Thesis
Progyny demonstrates strong financial health with a pristine balance sheet, excellent liquidity, and robust free cash flow generation. However, net income is flat YoY despite 10.4% revenue growth, signaling concerning margin compression and deteriorating operating leverage that requires immediate management attention.
Strengths
- Fortress balance sheet: $131.6M cash, zero debt, 2.13x current ratio provides substantial financial flexibility
- Strong free cash flow generation: $39.6M FCF (12.1% margin) demonstrates efficient cash conversion and low capital intensity
- Conservative capital structure: Asset-light business model with minimal CapEx ($6.3M) and no financial leverage
Risks
- Deteriorating profitability: Net income flat YoY (0% growth) despite 10.4% revenue growth indicates operating expenses outpacing top-line growth
- Poor capital efficiency: 5.5% ROE and 3.5% ROA are below industry standards, showing ineffective deployment of shareholder capital
- Margin compression concerns: 7.4% net margin and 25.3% gross margin are below typical healthcare services benchmarks
Key Metrics to Watch
- Operating margin and gross margin trends - critical to determine if compression is structural or temporary
- Net income growth rate relative to revenue growth - must demonstrate improving operating leverage
- Return on equity trajectory - essential for assessing long-term shareholder value creation potential
Financial Metrics
Revenue
328.5M
Net Income
24.2M
EPS (Diluted)
$0.29
Free Cash Flow
39.6M
Total Assets
698.3M
Cash
131.6M
Profitability Ratios
Gross Margin
25.3%
Operating Margin
10.8%
Net Margin
7.4%
ROE
5.5%
ROA
3.5%
FCF Margin
12.1%
Balance Sheet & Liquidity
Current Ratio
2.13x
Quick Ratio
2.13x
Debt/Equity
0.00x
Debt/Assets
37.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T12:28:56.390186 |
Data as of: 2026-03-31 |
Powered by Claude AI